A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

  1. Dawson, M.A.
  2. Borthakur, G.
  3. Huntly, B.J.P.
  4. Karadimitris, A.
  5. Alegre, A.
  6. Chaidos, A.
  7. Vogl, D.T.
  8. Pollyea, D.A.
  9. Davies, F.E.
  10. Morgan, G.J.
  11. Glass, J.L.
  12. Kamdar, M.
  13. Mateos, M.-V.
  14. Tovar, N.
  15. Yeh, P.
  16. Delgado, R.G.
  17. Basheer, F.
  18. Marando, L.
  19. Gallipoli, P.
  20. Wyce, A.
  21. Krishnatry, A.S.
  22. Barbash, O.
  23. Bakirtzi, E.
  24. Ferron-Brady, G.
  25. Karpinich, N.O.
  26. McCabe, M.T.
  27. Foley, S.W.
  28. Horner, T.
  29. Dhar, A.
  30. Kremer, B.E.
  31. Dickinson, M.
  32. Show all authors +
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1557-3265

Year of publication: 2023

Volume: 29

Issue: 4

Pages: 711-722

Type: Article

DOI: 10.1158/1078-0432.CCR-22-1284 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals